Pain is one of our core therapy areas and the Mundipharma network of independent associated companies in Europe has devoted over 35 years to learning about pain, understanding the mechanisms of pain and bringing new therapies for pain to the clinicians and patients who need them.
Our heritage in helping to treat and manage pain gives us a truly unique perspective from which to help shape the future of pain management. Many patients have failed on current pain medicines, there are patients for whom no treatment exists and patients who could benefit from a novel treatment – it is on these patients where we focus our efforts.
We have a broad portfolio of pain medicines and are always looking for what more can be done, what benefits can be realized in order to build an industry-leading pipeline to bring new pain medicines to the world that make a meaningful difference to patients.
Please note that the medicines mentioned may not be available in all countries. Additionally, currently approved indications and presentations may differ between countries. Please always ask a healthcare professional for advice regarding medicines and refer to individual countries for full product indication and local prescribing information.
Penthrox® (methoxyflurane) is a drug-device combination of an inhaler and methoxyflurane. Penthrox is licensed for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.
Targin® / Targinact®/ Targiniq® (oxycodone/naloxone) is a prolonged release tablet opioid for the treatment of severe pain, which can be adequately managed only with opioid analgesics and for the second-line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy. The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.
OxyNorm®(oxycodone) is an infusion or injection immediate release opioid for the treatment of moderate to severe pain in patients with cancer and post-operative pain and the treatment of severe pain requiring the use of a strong opioid.
OxyContin®/ OxyGesic® (oxycodone) is a prolonged release opioid tablet for the treatment of moderate to severe pain in patients with cancer and post-operative pain and for the treatment of severe pain requiring the use of a strong opioid.
BuTrans® / Norspan® (buprenorphine) is a transdermal patch opioid for the treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.
MST®Continus® (morphine sulphate) is a prolonged release tablet opioid treatment for the prolonged relief of severe and intractable pain, and for the relief of post-operative pain.
Palladon® / Palladone® / Hydal® (hydromorphone) is a prolonged release opioid capsule for the relief of severe pain in cancer.
Press return to search